Pfizer – Neoplasms

Submitted By:
Published Date:
January 25, 2020

Access Program Information

Primary objective of this study is to allow access and evaluate the safety of crizotinib for
patients in Japan with advanced NSCLC harboring a translocation or inversion involving the
ROS1 oncogene.